首页> 外文期刊>Modern Pathology >Ductal carcinoma in situ (DCIS): pathological features, differential diagnosis, prognostic factors and specimen evaluation
【24h】

Ductal carcinoma in situ (DCIS): pathological features, differential diagnosis, prognostic factors and specimen evaluation

机译:导管原位癌(DCIS):病理特征,鉴别诊断,预后因素和标本评估

获取原文
获取外文期刊封面目录资料

摘要

Ductal carcinoma in situ (DCIS) is a heterogeneous, unicentric precursor of invasive breast cancer, which is frequently identified through mammographic breast screening programs. The lesion can cause particular difficulties for specimen handling in the laboratory and typically requires even more diligent macroscopic assessment and sampling than invasive disease. Pitfalls and tips for macroscopic handling, microscopic diagnosis and assessment, including determination of prognostic factors, such as cytonuclear grade, presence or absence of necrosis, size of the lesion and distance to margins are described. All should be routinely included in histopathology reports of this disease; in order not to omit these clinically relevant details, synoptic reports, such as that produced by the College of American Pathologists are recommended. No biomarkers have been convincingly shown, and validated, to predict the behavior of DCIS till date.
机译:导管原位癌(DCIS)是浸润性乳腺癌的异质性,单中心性前体,通常通过乳腺X线摄影筛查程序进行识别。病变可能会给实验室中的标本处理带来特别的困难,并且通常需要比侵入性疾病更加勤奋的宏观评估和采样。描述了宏观处理,微观诊断和评估的陷阱和技巧,包括确定预后因素,例如细胞核等级,是否存在坏死,病变大小和距边缘的距离。所有这些应常规包括在该疾病的组织病理学报告中;为了不遗漏这些与临床相关的细节,建议提供天气摘要报告,例如美国病理学家学院撰写的摘要报告。迄今为止,还没有任何令人信服的生物标志物可以显示和验证DCIS的行为。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号